OurPet’s Company (OTCQX: OPCO) is tapping into the love that pet parents have for their beloved animal companions. The company specializes in providing feeding solutions for every dog, cat and home while making the pet-related waste management process a breeze.

Innovation inspires the product development efforts at OurPet’s. The company strives to develop one-of-a-kind products so that, unlike many of its competitors, it can offer products explicitly designed to nurture a healthy relationship between pets and their parents. Presently, most of the company’s products are patented and unmatched on the market.

OPCO’s unique product design process commences with an examination of the health, behavioral and lifestyle needs of pets and their parents. Once the company discovers innovative ways to fulfill these needs, it is able to offer impactful, problem-solving solutions to pet owners and highly-marketable products to retailers.

The company’s list of offerings features inventive toys that exercise a pet’s senses, as well as accessories, feeding and waste management solutions designed to stimulate a pet’s innate instincts.

OPCO’s operations are guided by thorough safety standards, developed using children’s product testing standards. In order to guarantee quality assurance, these principles are part of every product’s development and ongoing lifecycle. The company’s commitment to customer service is also noteworthy. Its customer service representatives, who assist customers via a toll-free number and e-mail address, cater to a broad set of needs, including general queries, product set-up and usage, and warranty and replacement questions.

OPCO’s business model has contributed significantly to its steady sales growth, but so have the markets in which it operates. In 2013, the pet products and services market was estimated at $71 billion, with forecasts calling for even more industry growth in the next few years. Considering this promise of future growth, OurPet’s seems well-placed for long-term success.

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

Ovarian cancer is a deadly disease and should be taken seriously. Early detection and monitoring of tumor development is the key to survival. If someone gets tested regularly and detects ovarian cancer early, their five-year survival rate can be as high as 93 percent, compared to a five-year survival rate of only 18 percent if detected in the later stages. Avant Diagnostics, Inc. (OTCQB: AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company’s first test, OvaDx, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

According to the American Cancer Society, more than 21,300 women were diagnosed with ovarian cancer last year, ultimately leading to 14,200 deaths. With early detection, your chances obviously improve, as mentioned above, so making the OvaDx test part of your annual checkup should be a no-brainer. Considering the ramifications of just going with the flow and cutting corners on regular monitoring of tumor development during the treatment process, one would ascertain that constant observation of which drugs are working and how well they are working would be greatly beneficial to the patient.

The ovarian cancer diagnostic market, where Avant Diagnostics competes, is worth more than $2 billion. With innovative, necessary testing procedures like OvaDx, the company is positioned to become a major game changer upon FDA approval. Some of the major players engaged in personalized medicine and molecular diagnostics involving biomarkers are global microarray market leader Affymetrix (NASDAQ: AFFX), which was recently reported as having been acquired by competitor Thermo Fisher Scientific (NYSE: TMO) for approximately $1.3 billion.

The standard approach to ovarian cancer utilizes the combination of a platinum compound, such as Bristol-Myers Squibb’s (NYSE: BMY) Platinol (cisplatin) or Paraplatin (carboplatin), and a Taxane, such as Sanofi’s (NYSE: SNY) Taxotere (docetaxel) or Phyton Biotech’s Taxol (paclitaxel). However, for patients with platinum-resistant/refractory ovarian cancer, early detection is really the brass ring, even with such good news out recently as Merck (NYSE: MRK) and Pfizer (NYSE: PFE) receiving FDA approval for the first Phase III study of avelumab, an investigational, fully human PD-L1 (programmed death-ligand 1) inhibitor that could emerge as a treatment for platinum-resistant/refractory ovarian cancer.

For more information, visit the company website at www.avantdiagnostics.com

Let us hear your thoughts: Avant Diagnostics, Inc. Message Board

For Alternet Systems, Inc. (OTCQB: ALYI), the world is its oyster. The company’s mission is to provide innovative solutions that facilitate and expedite commerce by enhancing customer experience and improving efficiency. To do so, it has transformed itself into an accelerator of high growth, emerging companies in the digital currency, multi-channel payments and mobile and digital security fields.

Alternet plans to make strategic investments in three high-growth markets. These are payment technology, financial technology, and data analytics. It’s been building the relationships to get things done. As part of its plan to enter into arrangements with select digital currencies, it has, since February 2014, through its wholly-owned subsidiary Alternet Financial Services, become an Authority for ven. Ven is a digital currency used in Hub Culture, an elite by-invitation-only social network founded in 2002. Ven is unique as a digital currency since, unlike other crypto-currencies, its value is determined by a weighted basket of currencies, commodities and carbon futures trading against major currencies at floating exchange rates. Consequently, it is also the first digital currency to float and the first to include carbon in its pricing, making it the only environmentally-linked currency in existence. Ven in circulation is completely backed by the reserve assets of major currencies, commodities and carbon futures.

The company has also entered into a strategic joint venture that leverages its knowledge of crypto-currencies. It is partnering with the Swiss company, Biometry AG, to integrate Biometry’s BioME into its existing payment system’s anti-money laundering and anti-fraud aspects, according to a report (http://dtn.fm/X7aGo) by Biometric Update. The use of BioMe will replace Alternet’s previous use of passwords and PINs with dynamic facial and voice recognition elements in the ID system and so provide end to end security for digital currencies. Biometry’s patented secure payment applications will be fully integrated into Alternet’s line of digital currency services, which includes OneMarket’s Digital Asset Exchange and the Alternet Financial Services, Digital Bank initiatives.

Alternet has also signed a Letter of Intent with P2P Cash to launch the Digital Asset Exchange initiative under the OneMarket subsidiary, subject to approval of the license by the New York Department of Financial Services. Under this Letter of Intent, the company plans to launch a digital currency exchange, fully compliant with government regulations and foreign exchange capabilities. The company is actively pursuing and preparing to apply for a license with The New York Department of Financial Services to be allowed to receive, transmit, store, exchange, issue or convert virtual currency for customers.

Alternet has also entered into a strategic channel partner agreement with BitPay – the world leader in business solutions for the Bitcoin digital currency. In October 2014, the company completed a formal agreement with Wildcard Consulting Inc. to launch the first U.S.-based Bitcoin debit card.

Alternet is being led to these milestones by Henryk Dabrowski, chairman and chief executive officer of Alternet Systems, Inc. Dabrowski has 25+ years’ experience in creating, leading and successfully harvesting information technology and telecom ventures on a global basis. Over the last 10 years, he has been actively investing in both public and privately held companies. He has extensive experience in emerging financial transactions platforms, including mobile wallets, convergent payments schemes, network file systems (NFS), stored value and prepaid services. From October 2009 to March 2014, Dabrowski was the chairman and CEO of Utiba Americas, a leading developer of mobile financial services software solutions, which, through his efforts, reached 66% market share in the Americas. Under his leadership, Utiba Americas, successfully engaged projects with America Movil, Digicel Group, Tigo, Citibank and several other banks and Mobile Network Operators. Utiba Americas was successfully and profitably sold to Amdocs (NASDAQ: DOX) in March 2014. Before that, Dabrowski was CEO of a joint venture with the Chinese firm Tianjin Contactless Payment Systems (TCPS), which provided multiple NFS prepaid fare collections systems for the transportation industry in the Americas.

For more information, visit www.alternetsystems.com

Let us hear your thoughts: Alternet Systems, Inc. Message Board

OurPet’s Company (OTCQX: OPCO) led all companies covered by The Bowser Report on Wednesday when its price per share surged by more than 10 percent. Bowser readers are likely already familiar with OPCO, as the company was featured in the publication’s November issue as its ‘Company of the Month’. In fact, OPCO has been recommended multiple times by Bowser’s panel of investment experts dating all the way back to May 2007.

In yesterday’s Daily Mover Alert, Thomas Rice, editor of The Bowser Report, detailed the specifics of OPCO’s big day by giving his opinion on the company as an option for prospective investors. His take was as follows:

Typical volatility from OPCO, but in a good direction this time. OPCO hit a high of $1 after we recommended the company in November 2015 at $0.90. Since, it has traded closer to $0.80 per share.

OCPO is currently in Category 1 with a Bowser Rating of 10. This is one to purchase if you’re looking to expand your portfolio. The price is right, and the company is doing well fundamentally.

OPCO may have some resistance moving up because of its low investor interest, but if investors take note of its steady growth, this stock could soar. In the meantime, if you have a position or enter a position, stick to the Game Plan!

OPCO’s strong performance in the rapidly expanding pet industry makes it an intriguing investment option moving forward. In 2013, the pet products and services market was valued at $71.3 billion, and additional industry growth is forecast for the coming years. OPCO is in a favorable strategic position to capitalize on this market performance through the use of its proven, two-pronged branding strategy, which includes the OurPets® brand for the pet specialty channel and the PetZone® brand for the food, drug and mass retail channel.

Over the past four years, OPCO has successfully leveraged this defined branding strategy, along with its extensive intellectual property portfolio, to record a 20.8 percent increase in sales while securing placements in nationwide retailers such as Walmart (NYSE: WMT), PetSmart, Petco and Kroger (NYSE: KR). Similarly, the company’s earnings have skyrocketed from $120,674 to $1.1 million since 2011.

The Bowser Report has been covering the most intriguing mini-priced stocks for just under 40 years. Utilizing a proprietary rating system and investing game plan, the report highlights the most promising stocks for long-term investment. Since 1976, The Bowser Report’s effectiveness has attracted tens of thousands of investors to the subscription-only newsletter.

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

Britannia Mining (OTC: BMIN), a natural resources development company focused on consolidating and trading a wide range of mineral commodities, this morning announced its partnership with Everledger Ltd. The alliance is of significance to Britannia’s vision for 2016, enabling the company to execute its growth strategy, address industry challenges by reducing risks, and add greater transparency in diamond procurement.

UK-based Everledger provides an immutable ledger for diamond certification and transaction verification in order to efficiently track the origin of diamonds. The company stores its ledger on the Blockchain, which was identified at the recent World Economic Forum in Davos as one of the fundamental elements of the Fourth Industrial Revolution.

For Britannia, this proprietary technology has the potential to incorporate tracking rough diamonds and possibly other high value minerals and metals from mine pit/shaft through to end-buyer.

“Our goal is to position the company to leverage the best practices for our downstream sales business. This year we plan to incorporate innovative and proven technologies to address some of the obstacles we have seen impede mineral commodity trading, such as slow inefficient paper based systems, risk, theft and fraud. We believe that this collaboration with Everledger presents the best opportunity for us to embrace state-of-the art digital solutions to reduce risk and improve the execution of trading deals,” Britannia CEO Kenneth Roberts stated in the news release.

Roberts provided more explanation of Britannia’s outlook for the upcoming year, indicating Everledger’s role in this plan.

“At the dawn of the Fourth Industrial Revolution, our vision is global and it is focused on addressing trading bottlenecks that are systemic. We anticipate announcing new major initiatives supporting this vision as this year progresses,” he said. “Managing risk lies at the heart of trading high value precious gems and metals. Digitization at source could go a long way to add value to due diligence, fraud detection, custody settlement and title transfer mechanisms. Last year we demonstrated that we can source quality products. This year, our focus is on adding an additional layer of transaction security to augment our offering and potentially speed up deal closing procedures.”

Roberts further outlines the company’s vision in an interview with Europe and Middle East Outlook Magazine (www.emeoutlookmag.com) scheduled for release January 29, 2016.

For more information, visit www.britanniamining.com

International Stem Cell Corporation (OTCQB: ISCO) is the company behind a powerful new stem cell technology called parthenogenesis, which promises to significantly advance the field of regenerative medicine by addressing the problem of immune-rejection. Derived from unfertilized eggs, the company’s human parthenogenetic stem cells (hPSCs) are pluripotent, meaning that they have the potential to become virtually any cell in the human body.

The first pluripotent stem cells to be studied for the purposes of regenerative medicine were embryonic stem cells (ESCs), which were taken from donated human embryos. While these cells could offer considerable healing potential, they also present a number of ethical concerns, because their production involves the destruction of a human embryo. ISCO’s hPSCs avoid these ethical issues while retaining many of the inherent advantages of ESCs.

One of the key factors limiting the advancement of regenerative medicine in the past has been the issue of immune-rejection. ESCs, much like transplanted organs, come with a high probability of rejection. This means that, after injection, the host’s immune system attacks the stem cells in an effort to prevent infection. When unfertilized human eggs undergo parthenogenesis, however, they inherit a duplicate set of human leukocyte antigen (HLA) genes, which greatly decrease the risk of immune-rejection. According to the company’s preclinical data, a relatively small number of hPSCs could be sufficient to provide ‘immune matched’ cells to a large percentage of the global population.

ISCO’s developmental pipeline includes a collection of hPSC-based treatments targeting severe diseases of the central nervous system, the liver and the eye. The company’s most advanced product candidate is for the treatment of Parkinson’s disease, which affects an estimated 10 million people worldwide and as many as one million in the United States alone. In preclinical studies, rodent and non-human primate subjects have shown measurable improvement in Parkinson’s disease symptoms and an increase in brain dopamine levels following the intracranial administration of hPSCs.

Last month, ISCO announced that it had entered into a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health of Australia, one of the world’s leading brain research centers, to conduct a phase I/IIa clinical trial of hPSCs in Parkinson’s disease patients. Under the terms of this agreement, ISCO will work with the Florey to conduct these studies at the Royal Melbourne Hospital.

“We recently received authorization to initiate Phase I/IIa and now we are moving forward toward formal engagement of the clinical site to conduct this study,” Russell Kern, PhD, executive vice president and chief scientific officer at ISCO, stated in a news release. “We expect to enroll all patients into the clinical trial in Q1 2016 and provide interim results in October 2016.”

For more information, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

Content Checked Holdings, Inc (OTCQB: CNCK) is a young company in a hurry. Founded in July 2013 by Kris Finstad, the company, according to SEC filings, had no revenues for the 6-month period ending September 30, 2014. One year later, for the comparable 6-month period to September 30, 2015, revenues of $657,850 flowed into the company’s coffers. Finstad and his team at Content Checked have not been sitting on their hands. Those hands have been busy creating and developing a family of mobile apps for those with special dietary needs or who suffer from food allergies.

The company’s first app, ContentChecked, is a smartphone application designed for use by those who suffer from food allergies and intolerances. The app allows its user to scan a product’s bar code and determine if it is safe for consumption. Other features include an expansive menu and recipe database with directions and ideas on food preparation for avoiding allergic reactions. ContentChecked also features a database of allergens and food ingredients that indicate any relationship between the two. Currently, that database has information on more than 400,000 products in the United States, and it’s constantly being expanded. ContentChecked doesn’t only help shoppers. The platform provides a way for food manufacturers and distributors to better inform their markets, where it matters most, at point-of-sale.

Subsequently, the company put out two more apps: MigraineChecked and SugarChecked. MigraineChecked is good news for the 38 million Americans who suffer from migraine and chronic headaches. With SugarChecked, you can scan the barcodes of grocery store products and determine the kind of sugars contained within. SugarChecked identifies four main types of sugars that consumers can avoid, including added sugars, artificial sweeteners, natural low-calorie sweeteners and sugar alcohols. The app is an easy shopping tool for consumers trying to decipher often-misleading food labels and receive recommendations for healthier alternative products in real time as they shop. It’s been estimated (http://dtn.fm/fX0tW) that, in the U.S., there are about 15 million people who suffer from food allergies. It’s a potentially fatal malaise, particularly in children (1 in 13 of whom is affected). According to a study released in 2013 by the Centers for Disease Control and Prevention (CDC), food allergies among children increased approximately 50 percent between 1997 and 2011. The economic cost of children’s food allergies is nearly $25 billion per year.

Together ContentChecked, MigraineChecked and SugarChecked have had over 2 million downloads, and 66 percent of users are active at least five times a week. These apps were initially meant for those who suffer from allergies and other dietary restrictions, but they’re catching on as the nation grows more health conscious. Last year, the U.S. Department of Agriculture, in a study entitled Changes in Eating Patterns and Diet Quality among Working-Age Adults, 2005-2010 reported that ‘American adults are eating better, making better use of available nutrition information… consuming fewer calories coming from fat and saturated fat, consuming less cholesterol and eating more fiber…’

The ContentChecked suite of apps has been talked about in Forbes, USA Today and the Los Angeles Business Journal. It’s been seen on ABC, CBS, NBC and Fox. Word is certainly getting around. CEO Kris Finstad is confident about the future: “We believe that the iOS (Apple) and Android platforms are moving in the direction of subscription-based applications. To capitalize on this trend and stay ahead of our competition, we are making our core apps free, and are also offering users subscription-based versions of our apps that will provide access to additional desired features. With the re-launch and re-brand of Content Checked’s products, anticipated to take place in March 2016, we will introduce a new subscription based service for the Content Checked line of products, in addition to offering an updated and improved experience for core (free) users.” We look forward to that.

For more information, visit www.contentchecked.com

Let us hear your thoughts: ContentChecked Holdings Inc. Message Board

The world’s countries differ in countless ways, but are similar in that they shoulder the task of protecting the health of their citizens. While the biggest health threats faced by emerging nations are communicable diseases such as HIV/AIDS, malaria and tuberculosis, these nations are also documenting rises in non-communicable disease such as cancer, diabetes and inflammatory disease. If drugs are available, many are hinged with high cost, complex administration and storage, significant side effects, or other challenges that prevent mass usage.

With decades of research behind it, naltrexone, or Lodonal™ as it is known internationally, is gaining global traction as a non-toxic, affordable and easy-to-administer therapy for both communicable and non-communicable diseases.

The U.S. FDA approved naltrexone 50 mg for the management of alcohol and opioid dependence in 1984; since then, many doctors in the United States have also prescribed low-dose naltrexone (LDN) to treat a number of indications, including multiple sclerosis (MS), Parkinson’s disease, Crohn’s disease, HIV/AIDS, cancer and other autoimmune and inflammatory diseases. While the mechanism of naltrexone in autoimmune diseases and cancer is still being researched, researchers have theories as to why LDN works on autoimmune diseases, cancer and inflammatory diseases.

In short, Lodonal/LDN helps the body heal itself by increasing the levels of endorphins (peptides produced in the brain and adrenal glands), which serve as powerful modulators of the body’s immune system. Lodonal attaches to opioid receptors in the brain and immune cells, temporarily blocking endorphins signals and causing the body to increase endorphin production. This boost of endorphin production helps facilitate the activity of stem cells, macrophages, natural killer cells, T and B cells and other immune cells. Lodonal also prevents immune system over activity, the crux of autoimmune disorders, and blunts the release of inflammatory and neurotoxic chemicals in the brain.

So how effective is LDN in such a wide range of indications? That’s what Orlando, Florida-based Immune Therapeutics, Inc. (OTCQB: IMUN) aims to find out. Immune Therapeutics has built a technology platform using patented immunotherapy to combat chronic, life-threatening diseases by activating and modulating the body’s immune system to enhance treatment.

The company’s most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) and LDN, the latter of which the company is pursuing in additional investigations as a viable treatment for autoimmune conditions such as rheumatoid arthritis and MS; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.

In collaboration with AHAR Pharma and GB Pharma Holdings, Immune Therapeutics recently completed a bridging trial comprised of HIV-positive patients to confirm the safety and efficacy of Lodonal. Resulting data was submitted to Nigeria’s National Agency for Food and Drug Administration Control (NAFDAC) in connection with approval of Lodonal as an immune booster to improve health of those affected by HIV-positive status and others with compromised immune systems.

This milestone is of particular importance in sub-Sharan Africa, where an estimated 24.7 million people – 71% of the global total – live with HIV. Ten countries account for 81% of all people living with HIV in the region, and 50% of those live in Nigeria and South Africa. Additionally, Immune Therapeutics reports that 80% of people who do not have access to HIV treatment are in Nigeria, which adds weight to the fact that Lodonal can provide non-toxic stand alone or adjunct treatment for less than $0.90 a day.

For more information on the specifics of the trial, visit https://www.immunetherapeutics.com/wp-content/uploads/2016/01/Lodonal_Bridging_Trial.pdf

In a news release announcing the completion, Dr. Nicholas Plotnikoff, Immune Therapeutics’ non-executive chairman, said, “We are excited about achieving this major milestone in collaboration with our partner organizations AHAR Pharma and GB Pharma Holdings. The shortened time frame of the Lodonal™ submission was facilitated by professionalism and thoroughness from NAFDAC. We look forward to continued cooperation with NAFDAC in the review of Lodonal™ in the hope of making a general immune booster and adjunct treatment for HIV+ patients.”

As part of this process, Immune Therapeutics in August 2015 signed a Letter of Intent with leading Nigerian pharmaceutical company Fidson Healthcare PLC for exclusive distribution rights in Nigeria and expects to finalize the agreement upon final NAFDAC approval for Lodonal.

HIV/AIDS remains one of three global public health threats, and, standing at the brink and waiting for NAFDAC approval for something with incredible potential to address this health concern, Immune Therapeutics continues to advance its pipeline for oncology and immunology – with LDN in phase 3 studies for MS, Chron’s UC and fibromyalgia and phase 2 studies for advanced cancers and HIV.

For more information visit www.immunetherapeutics.com

Earlier today, Alternet Systems, Inc. (OTCQB: ALYI) announced the launch of its Data Analytics Division, expanding upon the company’s portfolio of existing digital commerce technologies. Through this new division, Alternet will look to continue building upon its successful history of developing and commercializing innovative digital commerce technologies while broadening its focus into the burgeoning Big Data analytics sector.

“We quietly started the expansion last year after the successful sale of our mobile wallet solution,” Henryk Dabrowski, chief executive officer of Alternet, stated in the news release. “We anticipate our new Data Analytics Division to build upon the revenue base we established in 2015 from our digital commerce operations throughout the course of 2016.”

Alternet’s new Analytics-as-a-Service solutions will enable its clients to better understand consumer trends and improve their marketing initiatives. The company is already deploying cloud-based solutions addressing micro-segmentation and predictive analytics, including intuitive visualization tools and marketing automation. When used effectively, these solutions provide enhanced audience monetization by offering valuable audience insight that can be translated into market opportunities and automated sales and marketing responses.

The company’s cloud-based solutions also provide channel optimization through micro-segmentation analysis, allowing business owners to optimize their product and content listings while promoting growth through both physical and digital channels.

Following the launch of its Data Analytics Division, Alternet has established a presence in one of the world’s fastest-growing business sectors. According to the International Data Corporation, the Big Data technology and services market is expected to grow at a compound annual growth rate of 26.4 percent through 2018, roughly six times the growth rate of the overall information technology market.

Alternet continues to develop and commercialize a growing portfolio of digital commerce technologies in high-growth markets that address the expanding global dependence on technological conveniences and advances. As the company implements innovative solutions to the Big Data market, look for Alternet’s experienced management team to play a key role in promoting sustainable financial growth, building on its successful track record of developing and commercializing digital commerce technologies for both the United States and Latin American markets.

For more information, visit www.alternetsystems.com

Let us hear your thoughts: Alternet Systems, Inc. Message Board

Earlier today, GTX Corp. (OTC: GTXO), a global provider of GPS wearable technology, announced an agreement with Imexpalcom CIA Ltd. that will expand its distribution network into Central and South America. Imexpalcom is headquartered in Quito, Ecuador, and currently supports customers in both Ecuador and Colombia. It plans to expand into other countries in South America – including Peru and Bolivia – later this year.

“We are very excited to be launching this highly innovative product to the Ecuadorian and Colombian markets, finally we found the best solution for our market needs related to personal security,” Joffre Palacios, managing director of Imexpalcom, stated in the news release.

GTX Corp. has already shipped the first commercial order of its innovative GPS SmartSole™ to Imexpalcom, and additional shipments are scheduled to go out in the coming weeks. By pursuing and securing international expansion and partnerships in Latin America, the company is strategically positioning itself to promote considerable financial growth moving forward. GTX Corp.’s growing list of distributors already includes distribution partners across most of Europe.

“As we continue to expand our international business, we are extremely pleased to add Imexpalcom to our growing list of distributors and now with distribution partners across most of Europe, we are starting to focus a little more in Central and South America,” Andrew Duncan, director of business development for GTX Corp., stated in the release.

The company’s patented GPS SmartSole offers the benefits of advanced wearable tracking technology while eliminating the stigma commonly associated with these devices by placing the monitoring solution out of sight in the wearer’s shoe. In recent months, this groundbreaking approach to the needs of individuals with cognitive conditions that cause them to wander has been featured in AARP’s 2015 technology gear guide and in the 2015 New Product & Technology Awards, which recognize the most innovative products for older adults and their families.

Currently, more than 100 million people require oversight due to various forms of memory impairment, and it’s estimated that 60 percent of those individuals will become lost at least once. For people in danger of wandering and becoming lost due to Alzheimer’s disease, dementia, autism or traumatic brain injury, GTX Corp.’s wearable technology products and tracking devices can provide peace of mind and, in many cases, save lives.

For more information, visit www.gtxcorp.com

Let us hear your thoughts: GTX Corp. Message Board